1.David, MZ, Daum, RS. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews 2010; 23: 616–687.
2.Gutierrez, K, et al. Staphylococcal infections in children, California, USA, 1985–2009. Emerging Infectious Diseases 2013; 19: 10–20.
3.Boucher, HW, Corey, GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 2008; 46 (Suppl. 5): S344–349.
4.Klevens, RM, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Journal of the American Medical Association 2007; 298: 1763–1771.
5.Williamson, DA, et al. Increasing incidence and sociodemographic variation in community-onset Staphylococcus aureus skin and soft tissue infections in New Zealand children. Pediatric Infectious Disease Journal 2013; 32: 923–925.
6.Williamson, DA, et al. Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus in New Zealand: rapid emergence of sequence type 5 (ST5)-SCCmec-IV as the dominant community-associated MRSA clone. PLoS One 2013; 8: e62020.
7.de Kraker, ME, et al. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clinical Microbiology and Infection 2012; 19: 860–868.
8.Moran, GJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. New England Journal of Medicine 2006; 355: 666–674.
9.Muttaiyah, S, et al. Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. Journal of Clinical Microbiology 2010; 48: 3470–3474.
10.Hill, PC, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Internal Medicine Journal 2001; 31: 97–103.
11.Hill, PC, et al. Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand. Pediatric Infectious Disease Journal 2001; 20: 868–873.
12.O'Sullivan, CE, Baker, MG, Zhang, J. Increasing hospitalizations for serious skin infections in New Zealand children, 1990–2007. Epidemiology and Infection 2011; 139: 1794–1804.
13.Gordon, RJ, Lowy, FD. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clinical Infectious Diseases 2008; 46 (Suppl. 5): S350–359.
14.Tong, A, et al. Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies. PLoS One 2012; 7: e37212.
15.Shallcross, LJ, et al. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infectious Diseases 2103; 13: 43–54.
16.Tong, SY, et al. Clinical correlates of Panton-Valentine leukocidin (PVL), PVL isoforms, and clonal complex in the Staphylococcus aureus population of Northern Australia. Journal of Infectious Diseases 2010; 202: 760–769.
17.Lo, WT, Wang, CC. Panton-Valentine leukocidin in the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Pediatrics and Neonatology 2011; 52: 59–65.
18.Gillet, Y, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753–759.
19.Wehrhahn, MC, et al. Clinical and laboratory features of invasive community-onset methicillin-resistant Staphylococcus aureus infection: a prospective case-control study. European Journal of Clinical Microbiology & Infectious Diseases 2010; 29: 1025–1033.
20.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22, 2012.
21.World Health Organization. International statistical classification of diseases and related health problems – 10th revision, 2010.
22.Tracy, LA, et al. Predictive ability of positive clinical culture results and International Classification of Diseases, Ninth Revision, to identify and classify non-invasive Staphylococcus aureus infections: a validation study. Infection Control and Hospital Epidemiology 2010; 31: 694–700.
23.Monecke, S, et al. Microarray-based characterisation of a Panton-Valentine leukocidin-positive community-acquired strain of methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 2006; 12: 718–728.
24.Monecke, S, Slickers, P, Ehricht, R. Assignment of Staphylococcus aureus isolates to clonal complexes based on microarray analysis and pattern recognition. FEMS Immunology and Medical Microbiology 2008; 53: 237–251.
25.Monecke, S, et al. Rapid microarray-based identification of different mecA alleles in staphylococci. Antimicrobial Agents and Chemotherapy 2012; 56: 5547–5554.
27.Anderson, MJ. A new method for non-parametric multivariate analysis of variance. Australian Ecology 2001; 82: 290–297.
28.Fowler, VG Jr., et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. Journal of Infectious Diseases 2007; 196: 738–747.
29.Kurt, K, et al. Subpopulations of Staphylococcus aureus clonal complex 121 are associated with distinct clinical entities. PLoS One 2013; 8: e58155.
30.Munckhof, WJ, et al. Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. European Journal of Clinical Microbiology & Infectious Diseases 2008; 27: 355–364.
31.Zhao, C, et al. Characterization of community acquired Staphylococcus aureus associated with skin and soft tissue infection in Beijing: high prevalence of PVL+ ST398. PLoS One 2012; 7: e38577.
32.Orscheln, RC, et al. Contribution of genetically restricted, methicillin-susceptible strains to the ongoing epidemic of community-acquired Staphylococcus aureus infections. Clinical Infectious Diseases 2009; 49: 536–542.
33.Breurec, S, et al. Epidemiology of methicillin-susceptible Staphylococcus aureus lineages in five major African towns: high prevalence of Panton-Valentine leukocidin genes. Clinical Microbiology and Infection 2011; 17: 633–639.
34.Croze, M. Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clinical Microbiology and Infection 2009; 15: 144–148.
35.Hermos, CR, Yoong, P, Pier, GB. High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clinical Infectious Diseases 2010; 51: 1138–1146.
36.Williamson, DA, et al. Emergence and molecular characterization of clonal complex 398 (CC398) methicillin-resistant Staphylococcus aureus (MRSA) in New Zealand. Journal of Antimicrobial Chemotherapy. Published online: 22 December 2013. doi: 10.1093/jac/dkt499.